Axalta Coating Systems Ltd. disclosed second quarter 2026 financial results showing net sales growth of 3% to $1.346 billion and adjusted EBITDA expansion to $305 million, as the company advances toward shareholder and regulatory approval of its proposed merger of equals with Akzo Nobel N.V. The disclosure comes as Axalta shareholders prepare to vote on the transformational transaction on August 5, 2026, with completion estimated for late 2026 through early 2027. The companies have identified approximately $600 million in pre-tax run-rate cost synergies and targeted revenue uplift of 100–200 basis points above industry growth rates.
Key Points
- NYSE: AXTA
- Axalta reported Q2 2026 net sales of $1.346 billion, up 3% year-over-year, driven by acquisitions, positive price mix, and favorable foreign currency translation, partially offset by lower volumes
- Adjusted EBITDA reached $305 million in Q2 2026 compared to $292 million in Q2 2025, a 5% increase; adjusted diluted EPS grew 13% to $0.72
- Shareholder votes scheduled for August 5, 2026; merger completion targeted for late 2026 to early 2027 pending regulatory clearances
- Combined entity identified ~$600 million in pre-tax run-rate cost synergies with ~90% expected capture within three years post-close
Second Quarter Revenue and Earnings Performance
Axalta's second quarter 2026 net sales reached $1.346 billion, representing a 3% increase from $1.305 billion in the same quarter of 2025. The disclosure indicates that net sales growth was driven by foreign currency translation benefits, acquisitions completed during the period, and positive price mix, which were partially offset by lower volumes across the company's business segments. This mixed performance reflects both favorable market conditions in certain areas and headwinds in demand that warranted disclosure in the context of the merger announcement.
Adjusted EBITDA for the second quarter improved to $305 million from $292 million in the prior-year quarter, representing a $13 million or 5% increase. The filing states that this improvement was primarily attributable to lower operating and variable expenses, positive price mix realization, and the benefit of favorable foreign currency translation. The adjusted EBITDA margin expanded by 30 basis points to 22.7% in Q2 2026 compared to 22.4% in Q2 2025, indicating improved operational efficiency. Notably, the disclosure indicates that the second quarter results included an incremental $31 million of merger and acquisition-related costs primarily associated with the proposed merger with Akzo Nobel.
Profitability Metrics and Per-Share Results
Net income for the second quarter declined to $89 million in 2026 from $110 million in the prior year, a decrease of 19%, reflecting the impact of merger-related expenses and other non-recurring items that reduced earnings on a reported basis. However, the filing discloses that adjusted diluted earnings per share grew 13% to $0.72 in Q2 2026 from $0.64 in Q2 2025, demonstrating underlying profitability improvements when merger and acquisition costs are excluded from the calculation. This divergence between reported and adjusted earnings underscores the significant integration costs associated with the proposed combination.
Diluted earnings per share on a reported basis decreased 18% to $0.41 in the second quarter of 2026 compared to $0.50 in the prior-year period. The filing does not specifically itemize all components of the reported earnings decline beyond the disclosed merger-related costs, but the substantial gap between adjusted and reported diluted EPS highlights the materiality of transaction-related expenses in the second quarter. This metric is particularly relevant for shareholders evaluating the near-term financial impact of the combination.
Cash Flow Generation and Working Capital Improvements
Operating cash flow for the second quarter of 2026 totaled $152 million, up 7% from $142 million in the prior year. The filing states that cash provided by operating activities improved by $10 million, driven by enhanced working capital management and reduced interest payments compared to the second quarter of 2025. This improvement in cash generation during a period of substantial merger-related spending suggests that underlying operational cash flow production remains solid despite the transformation underway.
Free cash flow, calculated as operating cash flow less capital expenditures, reached $107 million in Q2 2026, compared to $101 million in Q2 2025, representing a 6% increase. The filing does not disclose specific capital expenditure figures for either period. The improvement in free cash flow demonstrates the company's ability to generate cash available for shareholders and debt service even as it manages the comprehensive costs associated with merger planning and integration preparation.
Merger Announcement Timeline and Regulatory Milestones
The merger of equals between Axalta and Akzo Nobel was announced on November 18, 2025, and has progressed through several critical regulatory and disclosure milestones. The filing indicates that a Form F-4 registration statement was filed with the U.S. Securities and Exchange Commission on May 27, 2026, and was amended on June 18, 2026. The SEC declared the registration statement effective on June 23, 2026, allowing the companies to commence mailing definitive proxy materials to shareholders on or about June 24, 2026.
Axalta's shareholders are scheduled to vote on the proposed merger at a special general meeting on August 5, 2026, while Akzo Nobel shareholders will vote at an extraordinary general meeting on the same date. The filing states that completion of the merger is estimated for late 2026 through early 2027, contingent upon receipt of necessary regulatory approvals. Following shareholder approval, the companies plan to accelerate integration planning, complete revenue synergy work with clean teams, announce the operating model, and unveil the management team of the combined entity.
Identified Cost and Revenue Synergies
The disclosure identifies approximately $600 million in pre-tax run-rate cost synergies expected from the combination of Axalta and Akzo Nobel. The filing states that the companies expect to capture approximately 90% of these identified synergies within the first three years following the close of the transaction. This substantial synergy target reflects the scale of operational integration and cost rationalization that management believes is achievable through the merger of equals structure.
Beyond cost synergies, the companies have identified targeted revenue synergy uplift of 100–200 basis points above industry growth rates. The filing does not provide specific revenue figures or detailed synergy itemization, but these targets suggest that management expects the combined entity to grow faster than its peer group through cross-selling opportunities, technology transfer, and market expansion strategies. The articulation of both cost and revenue synergies in the investor presentation indicates that the transaction is being positioned as offering multiple paths to value creation for shareholders.
Revenue Bridge Analysis and Segment Drivers
The filing presents a waterfall analysis showing how net sales grew from $1.305 billion in Q2 2025 to $1.346 billion in Q2 2026. Volume contributed a negative impact of approximately 0.8%, reflecting lower demand or reduced production across Axalta's customer base. However, this volume decline was more than offset by positive price and mix effects of approximately 0.4%, indicating successful execution of price realization strategies and favorable product mix shifts toward higher-margin offerings. These dynamics suggest a market environment where Axalta was able to offset volume pressure through pricing discipline and mix management.
Mergers and acquisitions contributed approximately 0.9% to net sales growth, while foreign currency translation added approximately 2.6% of the 3% total sales increase. This composition indicates that organic growth from pricing and mix was modest, organic volume was weak, but that inorganic growth from acquisitions and favorable currency movements provided meaningful support to top-line performance in the second quarter. The substantial foreign currency benefit highlights the international nature of Axalta's business and the exposure of reported results to exchange rate movements.
Post-Merger Integration and Management Planning
The filing describes the post-vote roadmap that Axalta and Akzo Nobel have established to move forward following shareholder approval. Key initiatives include accelerating integration planning to drive cost synergies realization, completing revenue synergy analysis with so-called clean teams to avoid conflicts of interest during the merger approval period, announcing the operating model of the combined entity, and unveiling the management team that will lead the integrated company. These specific workstreams suggest that the companies have advanced their combination planning significantly and are prepared to move quickly upon obtaining shareholder and regulatory approval.
The filing notes that Axalta is expected to be the sole listing of the combined company, with Akzo Nobel originally expected to have a separate listing for approximately 12 months following the close. This dual-listing structure provides a transition mechanism for Akzo Nobel shareholders while integrating the operations. The detailed post-vote roadmap indicates management confidence in the transaction structure and commitment to delivering the identified synergies through disciplined execution.
Merger-Related Costs and Financial Impact
The disclosure indicates that Axalta incurred an incremental $31 million in merger and acquisition-related costs in the second quarter of 2026, primarily associated with the proposed merger with Akzo Nobel. These costs are embedded in the company's reported financial results and represent a significant expense item that reduced net income and reported earnings per share in the quarter. The filing does not specify whether these costs are expected to continue at similar levels in subsequent quarters or provide a total estimated integration cost budget for the full transaction.
The separation of reported and adjusted earnings highlights the magnitude of near-term expenses associated with the merger process, including professional fees, regulatory compliance costs, and management time allocation. Investors evaluating the transaction should be aware that quarterly earnings results will continue to include material merger-related expenses through the completion and integration period, which extends into 2027 according to the filing's estimated completion timeline.
Regulatory Approval Status and Contingencies
The filing states that regulatory clearance approval is ongoing and represents a critical contingency for completion of the merger. While the disclosure does not identify specific regulatory jurisdictions or potential approval timeline challenges, it acknowledges that completion of the transaction is contingent upon receipt of necessary regulatory approvals. The estimated completion timeline of late 2026 through early 2027 implies that management expects regulatory approvals to be obtained during that window, although the filing offers no assurance regarding timing or the likelihood of approval.
The definitive proxy statement filed with the SEC on June 24, 2026, contains detailed disclosures regarding potential regulatory risks and the conditions to closing that relate to regulatory approval. The filing does not replicate those detailed risk disclosures in this investor presentation excerpt, but investors should review the complete proxy statement and registration statement for comprehensive discussion of regulatory contingencies and risks to completion.
NYSE Listing and Governance Structure
The filing confirms that the combined entity resulting from the merger of equals will be listed solely on the New York Stock Exchange under the Axalta name. This structure provides clarity regarding the primary equity listing for shareholders, although the filing indicates that Akzo Nobel shareholders may receive a separate listing for approximately 12 months following the close. The decision to consolidate onto a single NYSE listing suggests that management believes this structure maximizes liquidity and accessibility for the combined shareholder base.
The merger of equals structure itself carries governance implications, as both Axalta and Akzo Nobel shareholders are expected to hold meaningful stakes in the combined entity. The filing indicates that management teams from both companies are being retained or integrated, with the future management team to be unveiled following shareholder approval. This approach is intended to ensure continuity of leadership and operational expertise during the integration process.




Please wait processing your request...